Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q

Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis

(2021) Leonardo Javier Arcuri et al.   ANNALS OF HEMATOLOGY

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

(2021) Max Jan et al.   Nature Reviews Clinical Oncology

Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine

(2021) Tomomi Sato et al.   Frontiers in Cell and Developmental Biology

Cereblon Enhancer Methylation and IMiD Resistance in Multiple Myeloma

(2021) Larissa Haertle et al.   BLOOD

The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients

(2021) Joanna Barankiewicz et al.   Journal of Clinical Medicine

Lenalidomide in follicular lymphoma

(2020) Christopher Flowers et al.   BLOOD

Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro

(2020) Xiaofei He et al.   EXPERIMENTAL HEMATOLOGY

Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences

(2020) Sangeetha Venugopal et al.   BLOOD REVIEWS

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

(2020) Gilles Salles et al.   LANCET ONCOLOGY

Whole body deletion of Gpr68 does not change hematopoietic stem cell function

(2020) Xiaofei He et al.   Stem Cell Research

Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment

(2020) Antonio Piccolomo et al.   Cancers

Lenalidomide for the treatment of mantle cell lymphoma

(2019) Fortunato Morabito et al.   EXPERT OPINION ON PHARMACOTHERAPY

Ikaros tumor suppressor function includes induction of active enhancers and super-enhancers along with pioneering activity

(2019) Yali Ding et al.   LEUKEMIA

Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia

(2019) Takenobu Nii et al.   LEUKEMIA

Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re‐induction chemotherapy

(2019) Jacqueline S. Garcia et al.   AMERICAN JOURNAL OF HEMATOLOGY

A decade of progress in myelodysplastic syndrome with chromosome 5q deletion

(2018) Alan List et al.   LEUKEMIA

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

(2018) Franck Morschhauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML

(2018) Belen Lopez-Millan et al.   OncoImmunology

Molecular pathogenesis of myelodysplastic syndromes with deletion 5q

(2018) Jung-hoon Lee et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Lenalidomide in the treatment of chronic lymphocytic leukemia

(2017) Gilad Itchaki et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Contextual tumor suppressor function of T cell death-associated gene 8 (TDAG8) in hematological malignancies

(2017) Calvin R. Justus et al.   Journal of Translational Medicine

Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

(2017) Chetasi Talati et al.   SEMINARS IN HEMATOLOGY

Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis

(2016) Liang Liang et al.   ANNALS OF HEMATOLOGY

Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome

(2016) Mintallah Haider et al.   Clinical Lymphoma Myeloma & Leukemia

The molecular mechanism of thalidomide analogs in hematologic malignancies

(2016) Stefanie Lindner et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon

(2016) Thang Van Nguyen et al.   MOLECULAR CELL

A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes

(2016) Jing Fang et al.   NATURE MEDICINE

Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9

(2016) Rebekka K Schneider et al.   NATURE MEDICINE

Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis

(2016) Xin-yue Lian et al.   PLoS One

CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes

(2016) Wei Hseun Yeap et al.   Scientific Reports

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

(2015) R. S. Komrokji et al.   ANNALS OF ONCOLOGY

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma

(2015) T. E. Witzig et al.   ANNALS OF ONCOLOGY

Thalidomide-induced teratogenesis: History and mechanisms

(2015) Neil Vargesson   BIRTH DEFECTS RESEARCH PART C-EMBRYO TODAY-REVIEWS

The novel mechanism of lenalidomide activity

(2015) E. C. Fink et al.   BLOOD

Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond

(2015) Andrew A Guirguis et al.   CURRENT OPINION IN CELL BIOLOGY

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

(2015) Jan Krönke et al.   NATURE

Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide

(2014) Mahmoud R. Gaballa et al.   ANNALS OF HEMATOLOGY

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma

(2014) Shang-Yi Huang et al.   ANNALS OF HEMATOLOGY

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

(2014) Y. X. Zhu et al.   BLOOD

Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS

(2014) Rebekka K. Schneider et al.   CANCER CELL

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

(2014) Anna Jonasova et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia

(2014) Marcus Järås et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

(2014) Eric S. Fischer et al.   NATURE

Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs

(2014) Philip P Chamberlain et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

PP2A: The Achilles Heal in MDS with 5q Deletion

(2014) David A. Sallman et al.   Frontiers in Oncology

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes

(2013) Aristoteles Giagounidis et al.   ANNALS OF HEMATOLOGY

Deletion 5q MDS: Molecular and therapeutic implications

(2013) Rami S. Komrokji et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone

(2013) Daniel Heintel et al.   BRITISH JOURNAL OF HAEMATOLOGY

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients

(2013) G. Caceres et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Acidic tumor microenvironment and pH-sensing G protein-coupled receptors

(2013) Calvin R. Justus et al.   Frontiers in Physiology

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

(2012) A Lopez-Girona et al.   LEUKEMIA

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

(2012) Yuan Xiao Zhu et al.   LEUKEMIA & LYMPHOMA

Aiolos promotes TH17 differentiation by directly silencing Il2 expression

(2012) Francisco J Quintana et al.   NATURE IMMUNOLOGY

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

(2012) S Wei et al.   ONCOGENE

Lenalidomide Alone and in Combination for Chronic Lymphocytic Leukemia

(2012) Christine I. Chen   Current Hematologic Malignancy Reports

Functional modulation of AMP-activated protein kinase by cereblon

(2011) Kwang Min Lee et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

(2011) P. Fenaux et al.   BLOOD

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

(2011) L. Mollgard et al.   HAEMATOLOGICA

Consecutive Low Doses of Cyclosporine A Induce Pro-Inflammatory Cytokines and Accelerate Allograft Skin Rejection

(2011) Roberto López-Flores et al.   MOLECULES

Biology and treatment of the 5q- syndrome

(2011) Eric Padron et al.   Expert Review of Hematology

Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells

(2010) S. Dutt et al.   BLOOD

Whole blood flow cytometric measurement of NFATc1 and IL-2 expression to analyze cyclosporine A-mediated effects in T cells

(2010) Claudia Brandt et al.   CYTOMETRY PART A

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

(2010) Carla Heise et al.   Expert Review of Anticancer Therapy

Lenalidomide for Treatment of Myelodysplastic Syndromes: Current Status and Future Directions

(2010) Rami S. Komrokji et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis

(2010) A Matsuoka et al.   LEUKEMIA

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

(2010) Taimur Sher et al.   LEUKEMIA & LYMPHOMA

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

ATG plus Cyclosporine Reduces All-Cause Mortality in Patients with Severe Aplastic Anemia – Systematic Review and Meta-Analysis

(2009) Anat Gafter-Gvili et al.   ACTA HAEMATOLOGICA

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

(2009) Thomas M. Habermann et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion

(2009) M. Ximeri et al.   HAEMATOLOGICA

Low-dose cyclosporine is a good option for severe chronic urticaria

(2009) Aharon Kessel et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

(2009) Thomas E. Witzig et al.   JOURNAL OF CLINICAL ONCOLOGY

Involvement of Proton-Sensing TDAG8 in Extracellular Acidification-Induced Inhibition of Proinflammatory Cytokine Production in Peritoneal Macrophages

(2009) C. Mogi et al.   JOURNAL OF IMMUNOLOGY

PP2A regulates ionizing radiation-induced apoptosis through Ser46 phosphorylation of p53

(2009) J. Mi et al.   MOLECULAR CANCER THERAPEUTICS

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q– syndrome

(2009) Jillian L Barlow et al.   NATURE MEDICINE

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

(2009) S. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibitory Effects of Cyclosporine on Human Regulatory T Cells In Vitro

(2009) C. Miroux et al.   TRANSPLANTATION PROCEEDINGS

The role of lenalidomide in the management of myelodysplasia with del 5q

(2008) Charikleia Kelaidi et al.   BRITISH JOURNAL OF HAEMATOLOGY

The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia

(2008) Holger Nückel et al.   BRITISH JOURNAL OF HAEMATOLOGY

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

(2008) Christine Galustian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

(2008) L. Wu et al.   CLINICAL CANCER RESEARCH

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

(2008) Peter H. Wiernik et al.   JOURNAL OF CLINICAL ONCOLOGY

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

(2008) Ling Lu et al.   MICROVASCULAR RESEARCH

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

(2008) Benjamin L. Ebert et al.   NATURE

Dysregulation of large-conductance Ca2+-activated K+ channel expression in nonsyndromal mental retardation due to a cereblon p.R419X mutation

(2008) Joseph J. Higgins et al.   NEUROGENETICS